- FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings ( )
- FTC Sues to Block John Muir Health’s Takeover of San Ramon Regional Medical Center ( )
- FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book ( )
- FTC Sends Nearly $7 Million in Refunds to Consumers Harmed by Medical Discount Plans Sold as Health Insurance ( )
- FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’ ( )
- Statement Regarding Termination of CooperCompanies’ Attempted Acquisition of Cook Medical’s Reproductive Health Business ( )
- FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case ( )
- FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy ( )
- FTC Sues to Block IQVIA’s Acquisition of Propel Media to Prevent Increased Concentration in Health Care Programmatic Advertising ( )
- Federal Trade Commission Withdraws Health Care Enforcement Policy Statements ( )
- FTC Announces Tentative Agenda for July 20 Open Commission Meeting ( )
- FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market ( )
- FTC Policy Director Issues Statement Commending Maine’s Repeal of Certificate of Public Advantage Law ( )
- FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices ( )
- FTC Staff Opposes State Legislation in North Carolina Designed to Shield UNC Health System from Antitrust Enforcement ( )
- FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop ( )
- Statement Regarding the Termination of Boston Scientific Corporation’s Attempted Acquisition of a Majority Stake in M.I. Tech Co., Ltd. ( )
- FTC Proposes Amendments to Strengthen and Modernize the Health Breach Notification Rule ( )
- Ovulation Tracking App Premom Will be Barred from Sharing Health Data for Advertising Under Proposed FTC Order ( )
- FTC Deepens Inquiry into Prescription Drug Middlemen ( )
- FTC Sues to Block Biopharmaceutical Giant Amgen from Acquisition That Would Entrench Monopoly Drugs Used to Treat Two Serious Illnesses ( )
- FTC Releases Agenda for May 18 Workshop on Proposed Changes to the Eyeglass Rule ( )
- FTC Sends 37 New Cease and Desist Letters Regarding Agency’s Eyeglass Rule ( )
- FTC Sues to Stop the Potentially Illegal Integration of New Orleans Area Hospitals Over Failure to Follow Federal Reporting Law ( )
- FTC Approves Final Order against The Bountiful Company in First Case Alleging Hijacking of Online Product Reviews ( )
- FTC to Host Public Workshop on Proposed Changes to Its Ophthalmic Practice Rules, also Known as the Eyeglass Rule, in May in Washington, DC ( )
- FTC Approves Final Order against LCA-Vision, Halting Alleged Bait-and-Switch Advertising for LASIK Laser Eye Surgery ( )
- FTC Sends Cease and Desist Letters to Prescribers Regarding Potential Violations of the Commission’s Contact Lens Rule ( )
- Statement of Elizabeth Wilkins, Director of the FTC’s Office of Policy Planning, on the Decision of SUNY Upstate Medical University and Crouse Health System, Inc. to Drop Their Proposed Merger ( )
- FTC Order to Bar ZyCal Bioceuticals from Deceptive Health Marketing ( )
El .gov significa que es oficial.
Los sitios web del gobierno federal siempre usan un dominio .gov o .mil. Antes de compartir información confidencial en línea, asegúrese de estar en un sitio .gov o .mil.
Este sitio es seguro.
El https:// medios todos los datos transmitidos son cifrados - en otras palabras, cualquier información o el historial de navegación que proporcione se transmite de forma segura.